$4.61
1.32% yesterday
Nasdaq, Oct 13, 10:00 pm CET
ISIN
US46124U1079
Symbol
IVA

Inventiva - ADR Stock price

$4.61
-0.70 13.18% 1M
+1.32 40.14% 6M
+2.47 115.42% YTD
+1.94 72.66% 1Y
-0.69 13.02% 3Y
-9.17 66.55% 5Y
-8.81 65.65% 10Y
-8.81 65.65% 20Y
Nasdaq, Closing price Mon, Oct 13 2025
+0.06 1.32%
ISIN
US46124U1079
Symbol
IVA
Industry

Key metrics

Basic
Market capitalization
$640.9m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
40.7 | 24.9
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-89.6%
Return on Equity
172.7%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$15.8m | $25.7m
EBITDA
$-107.3m | $-134.5m
EBIT
$-113.7m | $-128.1m
Net Income
$-360.0m | -
Free Cash Flow
$-105.8m
Growth (TTM | estimate)
Revenue
-12.8% | 141.9%
EBITDA
4.3% | -28.9%
EBIT
1.8% | -15.4%
Net Income
-198.6% | -
Free Cash Flow
-7.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-681.1% | -522.6%
EBIT
-722.2%
Net
-2,285.4% | -
Free Cash Flow
-671.9%
More
EPS
$-3.3
FCF per Share
-
Short interest
0.0%
Employees
116
Rev per Employee
$90.0k
Show more

Is Inventiva - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

Inventiva - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Inventiva - ADR forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Inventiva - ADR forecast:

Buy
92%
Hold
8%

Financial data from Inventiva - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
16 16
13% 13%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
73% 73%
153%
- Research and Development Expense 100 100
14% 14%
633%
-107 -107
4% 4%
-681%
- Depreciation and Amortization 6.48 6.48
74% 74%
41%
EBIT (Operating Income) EBIT -114 -114
2% 2%
-722%
Net Profit -360 -360
199% 199%
-2,285%

In millions USD.

Don't miss a Thing! We will send you all news about Inventiva - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inventiva - ADR Stock News

Neutral
Seeking Alpha
5 days ago
Inventiva S.A. (NASDAQ:IVA ) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Development & Chief Medical Officer Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance Conference Call Participants William Alazawi Arun Sanyal Nezam H.
Neutral
GlobeNewsWire
7 days ago
Daix (France), New York City (New York, United States), October 7, 2025 -  Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced four abstracts presentations at the upcoming Annual American As...
Neutral
GlobeNewsWire
13 days ago
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (...
More Inventiva - ADR News

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Head office France
CEO Frédéric Cren
Employees 116
Founded 2011
Website inventivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today